The study showed that hypoxic culturing improves mesenchymal stem cell properties and positively influences whole genome expression profiles in reference to the development of cellular therapies targeting the microenvironment of the intervertebral disc.
The FDA authorized BioRestorative to move forward with a phase two clinical trial using hypoxic cultured bone marrow-derived mesenchymal stem cells in its lead candidate, BRTX-100, to treat chronic lower back pain.
BRTX-100 is cell therapy product formulated from autologous cultured mesenchymal stem cells collected from the patient’s bone marrow. The cells would then be isolated, cultured and cryopreserved before being injected into the patient’s damaged disc in an outpatient procedure.
More articles on biologics:
Steadman Philippon Research Institute to host Vail Scientific Summit: 4 things to know
U of Minnesota 3D-prints stem cells for spinal cord repair: 5 things to know
Key trends in cartilage repair for orthopedics: Q&A with Dr. Eric Strauss
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
